CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hainan Shuangcheng Phrmcutcls Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hainan Shuangcheng Phrmcutcls Co Ltd
No. 16, Xingguo Road, Xiuying District
Phone: +86 89868592978p:+86 89868592978 HAIKOU, HAN  570314  China Ticker: 002693002693
Business Summary
Hainan Shuangcheng Pharmaceuticals Co Ltd is a China-based company principally engaged in the research, development, production and sales of injectables, solid dosage forms, and active pharmaceutical ingredient. The Company operates its business through three segments. The Self-Production Pharmaceutical Sales segment produces and sells peptide drugs, as well as other pharmaceuticals such as bivalirudin for injection, famotidine for injection, and clindamycin hydrochloride for injection. The Trust Business segment provides research, development and technical services to other pharmaceutical companies. The Other Business segment primarily acts as an agent for other companies' pharmaceutical sales, as well as leasing land and buildings. The Company mainly conducts its businesses in the domestic market.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ChengdongWang 69 3/4/2017
Vice Chairman of the Board JingBai 40 1/26/2022 1/26/2022
Chief Financial Officer XuguangWang 57
9 additional Officers and Directors records available in full report.

General Information
Number of Employees: 446 (As of 12/31/2024)
Outstanding Shares: 414,689,750 (As of 6/30/2025)
Shareholders: 84,453
Stock Exchange: SHE
Fax Number: +86 89868592978


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, September 9, 2025
Register now for our FAST Rating webinar on September 10 at 2:00 PM ET!